Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PLEXUS CORP Director's Dealing 2022

Feb 2, 2022

31191_dirs_2022-02-02_6343083b-2610-4731-b8de-e7df3b35db1e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PLEXUS CORP (PLXS)
CIK: 0000785786
Period of Report: 2022-01-31

Reporting Person: Ninivaggi Angelo Michael Jr (Exec VP, CAO, Gen Coun & Secy)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-31 Restricted Stock Units $ A 5150 Acquired Common Stock (5150) Direct
2022-01-31 Performance Stock Units $ A 4780 Acquired Common Stock (4780) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock, $.01 par value 1455 Indirect
Common Stock, $.01 par value 31912 Direct

Footnotes

F1: Shares of Plexus Corp. common stock held in the Plexus Corp. 401(k) Retirement Plan as of the last report from the Plan's trustee.

F2: Each Restricted Stock Unit granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represents a contingent right to receive one share of Plexus Corp. common stock. The Restricted Stock Units vest on January 31, 2025.

F3: Each Performance Stock Unit ("PSU") granted under the Plexus Corp. 2016 Omnibus Incentive Plan, which qualifies under Rule 16b-3, represents a contingent right to receive one share of Plexus Corp. common stock if certain conditions are satisfied. Vesting of 2,200 PSUs is dependent on the relative total shareholder return ("TSR") of Plexus Corp.'s common stock as compared to companies in the S&P 400 Index and vesting of the remainder is based on goals related to economic return ("ER") during the three-year performance period. The target number of PSUs that may be earned is reported above. The reporting person may earn up to 150% of the targeted amount that is based on TSR and up to 200% of the targeted amount that is based on ER.